Sonoma Pharmaceuticals (SNOA) Accounts Payables (2011 - 2026)

Sonoma Pharmaceuticals' Accounts Payables history runs 16 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 136.31% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 136.31% increase from a year earlier, with the FY2026 full-year figure at $2.3 million, up 136.31% from the prior year.
• Accounts Payables climbed to $2.3 million in Q1 2026 per SNOA's latest filing, from $1.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $2.3 million in Q1 2026 and bottomed at $751000.0 in Q2 2024.
• The 5-year median for Accounts Payables is $1.8 million (2025), against an average of $1.7 million.
• Across the five-year window, Accounts Payables sank 60.75% in 2023 and surged 144.47% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $2.2 million in 2022, then sank by 60.75% to $864000.0 in 2023, then jumped by 121.76% to $1.9 million in 2024, then retreated by 14.09% to $1.6 million in 2025, then surged by 36.82% to $2.3 million in 2026.
• Per Business Quant, the three latest SNOA Accounts Payables figures stand at $2.3 million (Q1 2026), $1.6 million (Q4 2025), and $1.4 million (Q3 2025).